Ai Centrum Medyczne Sp. z o.o. S.K.

Poznan 19 trials 5 recruiting

19 Registered trials

5 Currently recruiting

Organisation

Ai Centrum Medyczne Sp. z o.o. S.K.

Location

Poznan, Poland

Identifier

ORG-100042715

Address

Ul. Swietojanska 1, 61-113, Poland

Departments

-
#408: Ai Centrum Medyczne Sp. z o.o. S.K.
40807: Ai Centrum Medyczne Sp. z o.o. S.K.
Ai Centrum Medyczne
Ai centrum medyczne Sp. z o.o. S.K
ai centrum medyczne sp. z o.o. sp.k.
N/A
NA
No Department
Outpatient Clinic
Practice

Clinical trials at this site (19)

Search interface

A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A study to test whether different doses of BI 3000202 help people with systemic lupus erythematosus (SLE) Recruiting

2025-523488-39-00 Systemic lupus erythematosus 4 2026-06-02
A study to learn if bimekizumab given in different ways is safe and moves similarly throughout the body over time in adults Recruiting

2025-522782-30-00 CCI 3 2026-04-07
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with… Recruiting

2024-513965-38-01 Sjögren's Disease 5 2025-06-16
A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting

2022-501354-10-01 axial spondyloarthritis 5 2023-06-21
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis. Ended

2022-501480-41-00 Psoriatic Arthritis 5 2023-04-06
A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in… Ended

2024-510826-16-00 Rheumatoid Arthritis 5 2025-04-07
A study to learn how well bimekizumab works and how safe it is in adults with psoriatic arthritis Ended

2024-511738-11-00 Psoriatic arthritis 5 2024-12-18
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to… Ended

2023-504564-42-00 Moderate to Severe Rheumatoid Arthritis 4 2024-04-08
A study to test if izokibep improves psoriatic arthritis symptoms and to see how safe izokibep is Ended

2022-501362-22-00 Psoriatic Arthritis 10 2023-04-18
A Study of Peresolimab (LY3462817) in Adults Participants With Moderately-to-Severely Active Rheumatoid Arthritis Ended

2022-501425-20-00 Rheumatoid Arthritis Arthritis Joint Diseases Muscul 4 2023-04-03
A Phase 3 Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus Ended

2022-500445-24-00 Moderately to Severely Active Systemic Lupus Erythemato 5 2022-11-30
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Su… Ended

2024-512142-42-00 Psoriatic Arthritis 5 2021-10-05
Guselkumab versus Placebo for the Treatment of Active Psoriatic Arthritis in Participants with Inadequate Response and/or Intolerance to One… Ended

2023-504715-33-00 Psoriatic Arthritis 5 2021-09-27
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experien… Ended

2023-507415-35-00 Psoriatic Arthritis 5 2021-01-15
Evaluation of upadacitinib in adult subjects with axial spondyloarthritis Ended

2022-501018-78-00 Axial Spondyloarthritis 5 2020-03-23
Phase 3b/4 Study in Rheumatoid Arthritis Ended

2023-508022-10-00 Rheumatoid Arthritis 6 2019-07-25